Role of telomerase in cell senescence and oncogenesis

Annual Review of Medicine

Volumn 51, Issue , 2000, Pages 65-79

  Urquidi, Virginia ^a   Tarin, David ^a   Goodison, Steve ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immortality; Replicative lifespan; Reverse transcriptase; Therapeutic target; Tumor marker

Indexed keywords

RNA DIRECTED DNA POLYMERASE; TELOMERASE; TUMOR MARKER;

CANCER; CARCINOGENESIS; CELL DEATH; CELL DIVISION; CELL PROLIFERATION; DNA SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REACTIVATION; ENZYME REGULATION; ENZYME STRUCTURE; HUMAN; PRIORITY JOURNAL; REVIEW; TELOMERE;

CELL AGING; DNA REPLICATION; HUMANS; NEOPLASMS; TELOMERASE; TELOMERE; TUMOR MARKERS, BIOLOGICAL;

EID: 0034006777     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.51.1.65     Document Type: Review

References (90)

1. 1. Greider CW. 1996. Telomere length regulation. Annu. Rev. Biochem. 65:337-65
2. 2. Sandell LL, Zakian VA. 1993. Loss of a yeast telomere: arrest, recovery, and chromosome loss. Cell 75:729-39
3. 3. Kirk KE, Harmon BP, Reichardt IK, et al. 1997. Block in anaphase chromosome separation caused by a telomerase template mutation. Science 275:1478-81
4. 4. Shore DA. 1995. Telomere position effects and transcriptional silencing in the yeast Saccharomyces cerevisiae. In Telomeres, ed. EH Blackburn, CW Greider, pp. 139-91. Cold Spring Harbor, NY: Cold Spring Harbor Lab.
5. 5. Wellinger RJ, Sen D. 1997. The DNA structures at the ends of eukaryotic chromosomes. Eur. J. Cancer 33:735-49
6. 6. Lansdorp PM, Verwoerd NP, van de Rijke FM, et al. 1996. Heterogeneity in telomere length of human chromosomes. Hum. Mol. Genet. 5:685-91
7. 7. Blackburn EH. 1997. The telomere and telomerase: nucleic acid-protein complexes acting in a telomere homeostasis system. A review. Biochemistry (Moscow) 62:1196-201
8. 8. Broccoli D, Smogorzewska A, Chong L, de Lange T. 1997. Human telomeres contain two distinct Myb-related proteins, TRF1 andTRF2. Nat. Genet. 17:231-35
9. 9. van Steensel B, de Lange T. 1997. Control of telomere length by the human telomeric protein TRF1. Nature 385: 740-43
10. 10. Watson JD. 1972. Origin of concatemeric T4 DNA. Nat. New Biol. 239:197-201
11. 11. Olovnikov AM. 1973. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J. Theor. Biol. 41:181-190
12. 12. Sedivy JM. 1998. Can ends justify the means? Telomeres and the mechanisms of replicative senescence and immortalization in mammalian cells. Proc. Natl. Acad. Sci. USA 95:9078-81
13. 13. Counter CM, Avilion AA, LeFeuvre CE, et al. 1992. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11:1921-29
14. 14. Shay JW, Wright WE, Werbin H. 1991. Defining the molecular mechanisms of human cell immortalization. Biochim. Biophys. Acta 1072:1-7
15. 15. Shay JW, Wright WE. 1989. Quantitation of the frequency of immortalization of normal human diploid fibroblasts by SV40 large T-antigen. Exp. Cell Res. 184:109-18
16. 16. Radna RL, Caton Y, Jha KK, et al. 1989. Growth of immortal simian virus 40 tsA-transformed human fibroblasts is temperature dependent. Mol. Cell Biol. 9:3093-96
17. 17. Harley CB, Futcher AB, Greider CW. 1990. Telomeres shorten during ageing of human fibroblasts. Nature 345:458-60
18. 18. Hastie ND, Dempster M, Dunlop MG, et al. 1990. Telomere reduction in human colorectal carcinoma and with ageing. Nature 346:866-68
19. 19. Feng J, Funk WD, Wang SS, et al. 1995. The RNA component of human telomerase. Science 269:1236-41
20. 20. Kondo Y, Kondo S, Tanaka Y, et al. 1998. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene 16:2243-48
21. 21. Bodnar AG, Ouellette M, Frolkis M, et al. 1998. Extension of life-span by introduction of telomerase into normal human cells. Science 279:349-52
22. 22. Vaziri H, Benchimol S. 1998. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 8:279-82
23. 23. Halvorsen TL, Leibowitz G, Levine F. 1999. Telomerase activity is sufficient to allow transformed cells to escape from crisis. Mol. Cell Biol. 19:1864-70
24. 24. Greider CW, Blackburn EH. 1985. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43:405-13
25. 25. Nakamura TM, Morin GB, Chapman KB, et al. 1997. Telomerase catalytic subunit homologs from fission yeast and human. Science 277:955-59
26. 26. Harrington L, Zhou W, McPhail T, et al. 1997. Human telomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev. 11:3109-15
27. 27. Kilian A, Bowtell DD, Abud HE, et al. 1997. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet. 6:2011-19
28. 28. Holt SE, Aisner DL, Baur J, et al. 1999. Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev. 13:817-826
29. 29. Harrington L, McPhail T, Mar V, et al. 1997. A mammalian telomerase-associated protein. Science 275:973-77
30. 30. Nakayama J, Saito M, Nakamura H, et al. 1997. TLP1: a gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family. Cell 88:875-84
31. 31. Zhu J, Wang H, Bishop JM, Blackburn EH. 1999. Telomerase extends the life-span of virus-transformed human cells without net telomere lengthening. Proc. Natl. Acad. Sci. USA 96:3723-28
32. 32. Jiang XR, Jimenez G, Chang E, et al. 1999. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nat. Genet. 21:111-14
33. 33. Morales CP, Holt SE, Ouellette M, et al. 1999. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat. Genet. 21:115-18
34. 34. Avilion AA, Piatyszek MA, Gupta J, et al. 1996. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res. 56:645-50
35. 35. Takakura M, Kyo S, Kanaya T, et al. 1998. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res. 58:1558-61
36. 36. Ulaner GA, Giudice LC. 1997. Developmental regulation of telomerase activity in human fetal tissues during gestation. Mol. Hum. Reprod. 3:769-73
37. 37. Sharma HW, Sokoloski JA, Ferez JR, et al. 1995. Differentiation of immortal cells inhibits telomerase activity. Proc. Natl. Acad. Sci. USA 92:12343-46
38. 38. Bestilny LJ, Brown CB, Miura Y, et al. 1996. Selective inhibition of telomerase activity during terminal differentiation of immortal cell lines. Cancer Res. 56: 3796-802
39. 39. Weng NP, Palmer LD, Levine BL, et al. 1997. Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging. Immunol. Rev. 160:43-54
40. 40. Liu K, Schoonmaker MM, Levine BL, et al. 1999. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. Proc. Natl. Acad. Sci. USA 96: 5147-52
41. 41. Tanaka H, Shimizu M, Horikawa I, et al. 1998. Evidence for a putative telomerase repressor gene in the 3p14.2-p21.1 region. Genes Chromosomes Cancer 23: 123-33
42. 42. Cuthbert AP, Bond J, Trott DA, et al. 1999. Telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest in human breast cancer cells [see comments]. J. Natl. Cancer Inst. 91:37-45
43. 43. Kiaris H, Schally AV. 1999. Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone. Proc. Natl. Acad. Sci. USA 96:226-31
44. 44. Greenberg RA, O'Hagan RC, Deng H, et al. 1999. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 18:1219-26
45. 45. Wu KJ, Grandori C, Amacker M, et al. 1999. Direct activation of TERT transcription by c-MYC. Nat. Genet. 21: 220-24
46. 46. Ulaner GA, Hu JF, Vu TH, et al. 1998. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res. 58:4168-72
47. 47. Li H, Zhao LL, Funder JW, Liu JP. 1997. Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells. J Biol. Chem. 272:16729-32
48. 48. Li H, Zhao L, Yang Z, et al. 1998. Telomerase is controlled by protein kinase C alpha in human breast cancer cells. J. Biol. Chem. 273:33436-42
49. 49. Kang SS, Kwon T, Kwon DY, Do SI. 1999. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J. Biol. Chem. 274:13085-90
50. 50. Kim NW, Piatyszek MA, Prowse KR, et al. 1994. Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-15
51. 51. Shay JW, Bacchetti S. 1997. A survey of telomerase activity in human cancer. Eur. J. Cancer 33:787-91
52. 52. Meeker AK, Coffey DS. 1997. Telomerase: a promising marker of biological immortality of germ, stem, and cancer cells. A review. Biochemistry (Moscow) 62:1323-31
53. 53. Sugino T, Yoshida K, Bolodeoku J, et al. 1996. Telomerase activity in human breast cancer and benign breast lesions: diagnostic applications in clinical specimens, including fine needle aspirates. Int. J. Cancer 69:301-6
54. 54. Aogi K, Kitahara K, Buley I, et al. 1998. Telomerase activity in lesions of the thyroid: application to diagnosis of clinical samples including fine-needle aspirates. Clin. Cancer Res. 4:1965-70
55. 55. Gorham H, Yoshida K, Sugino T, et al. 1997. Telomerase activity in human gynaecological malignancies. J. Clin. Pathol. 50:501-4
56. 56. Duggan BD, Wan M, Yu MC, et al. 1998. Detection of ovarian cancer cells: comparison of a telomerase assay and cytologic examination. J. Natl. Cancer Inst. 90:238-42
57. 57. Califano J, Ahrendt SA, Meininger G, et al. 1996. Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. Cancer Res. 56:5720-22
58. 58. Yoshida K, Sugino T, Tahara H, et al. 1997. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 79:362-69
59. 59. Kinoshita H, Ogawa O, Kakehi Y, et al. 1997. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J. Natl. Cancer Inst. 89:724-30
60. 60. Gupta J, Han LP, Wang P, et al. 1996. Development of retinoblastoma in the absence of telomerase activity. J. Natl. Cancer Inst. 88:1152-57
61. 61. DeMasters BK, Markham N, Lillehei KO, Shroyer KR. 1997. Differential telomerase expression in human primary intracranial tumors. Am. J. Clin. Pathol. 107:548-54
62. 62. Langford LA, Piatyszek MA, Xu R, et al. 1995. Telomerase activity in human brain tumours. Lancet 346:1267-68
63. 63. Broccoli D, Young JW, de Lange T. 1995. Telomerase activity in normal and malignant hematopoietic cells. Proc. Natl. Acad. Sci. USA 92:9082-86
64. 64. Brien TP, Kallakury BV, Lowry CV, et al. 1997. Telomerase activity in benign endometrium and endometrial carcinoma. Cancer Res. 57:2760-64
65. 65. Yashima K, Piatyszek MA, Saboorian HM, et al. 1997. Telomerase activity and in situ telomerase RNA expression in malignant and non-malignant lymph nodes. J. Clin. Pathol. 50:110-17
66. 66. Tahara H, Yasui W, Tahara E, et al. 1999. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 18:1561-67
67. 67. Weil RJ, Wu YY, Vortmeyer AO, et al. 1999. Telomerase activity in microdissected human gliomas. Mod. Pathol. 12:41-66
68. 68. Soder AI, Hoare SF, Muir S, et al. 1997. Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene 14:1013-21
69. 69. Blasco MA, Rizen M, Greider CW, Hanahan D. 1996. Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nat. Genet. 12:200-4
70. 70. Meyerson M, Counter CM, Eaton EN, et al. 1997. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90:785-95
71. 71. Ramakrishnan S, Eppenberger U, Mueller H, et al. 1998. Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res. 58:622-25
72. 72. Pao CC, Tseng CJ, Lin CY, et al. 1997. Differential expression of telomerase activity in human cervical cancer and cervical intraepithelial neoplasia lesions. J. Clin. Oncol 15:1932-37
73. 73. Kyo S, Takakura M, Ishikawa H, et al. 1997. Application of telomerase assay for the screening of cervical lesions. Cancer Res. 57:1863-67
74. 74. Zhang W, Kapusta LR, Slingerland JM, Klotz LH. 1998. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res. 58:619-21
75. 75. Uchida N, Otsuka T, Arima F, et al. 1999. Correlation of telomerase activity with development and progression of adult T-cell leukemia. Leukemia Res. 23:311-16
76. 76. Langford LA, Piatyszek MA, Xu R, et al. 1997. Telomerase activity in ordinary meningiomas predicts poor outcome. Hum. Pathol. 28:416-20
77. 77. Hiyama E, Hiyama K, Yokoyama T, et al. 1995. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat. Med. 1:249-55
78. 78. Hiyama E, Gollahon L, Kataoka T, et al. 1996. Telomerase activity in human breast tumors. J. Natl. Cancer Inst. 88:116-22
79. 79. Maitra A, Yashima K, Rathi A, et al. 1999. The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblaslic tumors. Cancer 85:741-49
80. 80. Hisatomi H, Nagao K, Kanamaru T, et al. 1999. Levels of telomerase catalytic subunit mRNA as a predictor of potential malignancy. Int. J. Oncol. 14:727-32
81. 81. Bacchetti S. 1996. Telomere maintenance in tumour cells. Cancer Surv. 28:197-216
82. 82. Strahl C, Blackburn EH. 1996. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol. Cell Biol. 16:53-65
83. 83. Mata JE, Joshi SS, Palen B, et al. 1997. A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo. Toxicol. Appl. Pharmacol. 144:189-97
84. 84. Yokoyama Y, Takahashi Y, Shinohara A, et al. 1998. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res. 58:5406-10
85. 85. Kondo S, Tanaka Y, Kondo Y, et al. 1998. Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation. FASEB J. 12:801-11
86. 86. Norton JC, Piatyszek MA, Wright WE, et al. 1996. Inhibition of human telomerase activity by peptide nucleic acids. Nat. Biotechnol. 14:615-19
87. 87. Sun D, Thompson B, Cathers BE, et al. 1997. Inhibition of human telomerase by a G-quadruplex-interactive compound. J. Med. Chem. 40:2113-16
88. 88. Ishikawa F. 1997. Regulation mechanisms of mammalian telomerase. A review. Biochemistry (Moscow) 62: 1332-37
89. 89. Bryan TM, Englezou A, Dalla-Pozza L, et al. 1997. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med. 3:1271-74
90. 90. Parkinson EK. 1996. Do telomerase antagonists represent a novel anti-cancer strategy? Br. J. Cancer 73:1-4